RecruitingNCT06576180

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma: a Prospective Cohort Study


Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrollment

306 participants

Start Date

Aug 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on cognitive function in patients with resectable head and neck squamous cell carcinoma: a prospective cohort study


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how chemotherapy and immunotherapy before surgery for head and neck cancer affects thinking and memory (cognitive function) in patients in China. Researchers want to understand if these treatments cause any mental fog or thinking changes. **You may be eligible if...** - You have been diagnosed with head and neck squamous cell carcinoma (stage I–IVA) and have not yet received treatment - You are planned for surgery, with or without chemotherapy and immunotherapy - You can speak Chinese and have basic reading/writing ability **You may NOT be eligible if...** - You have a brain tumor, brain injury, or any neurological condition - You have previously had a different type of cancer (other than skin cancer) - You have serious psychiatric illness - You are unable to cooperate with cognitive testing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCarboplatin( neoadjuvant)

Carboplatin (IV), AUC=5,administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

DRUGPaclitaxel (neoadjuvant)

Paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

DRUGAnti-PD-1 Drugs

Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

PROCEDURESurgical resection

Standard of care


Locations(1)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Guanzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06576180


Related Trials